GRNA(Delisted)
GreenLight·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GRNA
Greenlight Biosciences Holdings
A biotechnology company that develops an RNA platform for agriculture and human health
200 Boston Avenue, Medford, Massachusetts 02155
--
GreenLight Biosciences Holdings was incorporated in Delaware on July 2, 2020. GreenLight Biosciences aims to solve some of the world's biggest problems by realizing the full potential of RNA for human health and agriculture. Their RNA platforms enable the research, design and manufacture of human, animal and plant health. In human health, this includes mRNA vaccines and therapeutic agents. In agriculture, this includes RNA that protects bees and a range of crops. The company's platform is protected by a number of patents. GreenLight's human health product candidates are in the preclinical stage, and its product candidates for the agricultural market are in the early stages of development or regulatory review.
Company Financials
EPS
GRNA has released its 2023 Q1 earnings. EPS was reported at -0.19, versus the expected -0.23, beating expectations. The chart below visualizes how GRNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GRNA has released its 2023 Q1 earnings report, with revenue of 3.82M, reflecting a YoY change of 1386.38%, and net profit of -28.47M, showing a YoY change of 25.49%. The Sankey diagram below clearly presents GRNA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
